Kerry M. Clem - 10 Nov 2026 Form 4 Insider Report for OS Therapies Inc (OSTX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 16:30:36 UTC
Prior SEC filing
30 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kerry M. Clem
Filing notes and source

Key filing fact

Kerry M. Clem filed Form 4 for OS Therapies Inc (OSTX) on 12 Nov 2026.

Key facts

  • This page summarizes Kerry M. Clem's Form 4 filing for OS Therapies Inc (OSTX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 30 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001883938 Primary reporting owner

Clem Kerry M

Relationship
Chief Commercial Officer
Address
C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE
Signature
/s/ Kerry M. Clem
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OSTX transaction

Common Stock

Award

Transaction value
Shares
+200,000
Change %
+800%
Price
$0.000000*
Shares after
225,000
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OSTX transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares
+700,000
Change %
Price
$0.000000*
Shares after
700,000
Date
10 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
700,000
Exercise price
$0.8900
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 10, 2026 (the "Grant Date"), the reporting person was granted 200,000 restricted stock units ("RSUs") pursuant to the terms and conditions of a restricted stock unit award agreement and the issuer's amended and restated 2023 incentive compensation plan. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting and settlement. 20% of the RSUs vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

Footnote F2

On the Grant Date, the reporting person was granted options to purchase 700,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. 20% of these options vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .